Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. - Wikidata - wikimedia - TriplyDB

Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies.

Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies.

http://www.wikidata.org/entity/Q34632118

about

Targeting toll-like receptors: promising therapeutic strategies for the management of sepsis-associated pathology and infectious diseases Skin TLR7 triggering promotes accumulation of respiratory dendritic cells and natural killer cells Hepatitis C and Innate Immunity: Recent Advances Hepatitis C Virus Is a Weak Inducer of Interferon Alpha in Plasmacytoid Dendritic Cells in Comparison with Influenza and Human Herpesvirus Type-1 High throughput screening for small molecule enhancers of the interferon signaling pathway to drive next-generation antiviral drug discovery Toll-like receptor 7 agonists: chemical feature based pharmacophore identification and molecular docking studies Tickling the TLR7 to cure viral hepatitis.The therapeutic potential of Toll-like receptor 7 stimulation in asthma.Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release.R-848 triggers the expression of TLR7/8 and suppresses HIV replication in monocytes A phase II dose-ranging study of topical resiquimod to treat actinic keratosis.The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system.Use of modelling and simulation techniques to support decision making on the progression of PF-04878691, a TLR7 agonist being developed for hepatitis C Upping the antedrug: is a novel anti-inflammatory Toll-like receptor 7 agonist also a bronchodilator?Biological characterization of a novel class of toll-like receptor 7 agonists designed to have reduced systemic activity Trial Watch: Experimental Toll-like receptor agonists for cancer therapy Tolerability in man following inhalation dosing of the selective TLR7 agonist, AZD8848.IFN-α subtypes: distinct biological activities in anti-viral therapy.GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees.Toll-like receptor 7 affects the pathogenesis of non-alcoholic fatty liver disease.TLR-7 activation enhances IL-22-mediated colonization resistance against vancomycin-resistant enterococcus.Evaluation of mucosal adjuvants and immunization routes for the induction of systemic and mucosal humoral immune responses in macaques.Liposomal resiquimod for the treatment of Leishmania donovani infection.Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer.HCV drug discovery aimed at viral eradication.New NS5B polymerase inhibitors for hepatitis C.Toll-like receptor modulators: a patent review (2006-2010).The type I interferon response during viral infections: a "SWOT" analysis.Prophylactic and therapeutic implications of toll-like receptor ligands.Preclinical development of TLR ligands as drugs for the treatment of chronic viral infections.Resiquimod, a topical drug for viral skin lesions and skin cancer.Adjuvant immunotherapies as a novel approach to bacterial infections.Innate immunity in systemic sclerosis pathogenesis.Monocyte/macrophage inflammatory response pathways to combat Francisella infection: possible therapeutic targets?Promising Role of Toll-Like Receptor 8 Agonist in Concert with Prostratin for Activation of Silent HIV.An Enzyme-Directed Imidazoquinoline for Cancer Immunotherapy.Strategies for designing synthetic immune agonists.Cognitive impairment in relation to depression, anxiety and virological response in hepatitis C patients in Egypt.Anti-tumor Activity of Toll-Like Receptor 7 Agonists.TLR7/8 ligand, R-848, inhibits IgE synthesis by acting directly on B lymphocytes.

P2860

Q27010345-8FCBD116-5199-4C7C-9E66-B81AD9473963 Q27323190-9B592BAB-65D2-45B5-97BA-C00A90350688 Q27487394-52431B22-34D9-4EF2-971B-6E4927F3FFF1 Q27487765-64669EFC-BEFE-428B-8226-5DAFF55F34B6 Q28483402-1D4D36BD-31D5-4139-98D7-60C83A49BF27 Q28488415-0F30933E-003B-463F-BA79-6C7901981C15 Q33690260-D1276597-7E0F-45B6-8C66-B9E133F4FC8F Q33725167-333F3162-EBE1-44E2-932F-64F31E992771 Q33760871-878ECC9D-CA29-4238-828C-89510D360760 Q34127415-BEB63211-F5D1-48D8-9FA2-6977D5686C25 Q34778360-70666BB5-08B2-4B7B-98EA-BF83D4C8658D Q35018021-1D29ABFE-473E-460E-8750-3B31C7CB9B9C Q35640461-C318C32A-DE75-4F8C-91A3-F2B7C14858B2 Q36159164-0C390981-C000-4F9A-9AC7-3726AB0C95D1 Q36159174-61206867-9351-43FB-89B3-FF0B2B18638C Q36194849-795447C9-811F-4CE4-9A68-1DCB8371E684 Q36625355-5A05F96D-DD11-40AB-82E0-88B9D296508A Q36675798-143052C7-EDF3-4AA3-B5AC-96671E6DC2B1 Q36950984-7766D66F-01B1-44A0-BFA5-1151285BDEDF Q36986160-DFCF9640-B515-4E4F-9019-9C2B6E0594C2 Q37190661-FFB06E20-9459-4381-AB5E-B2A8374D9ED1 Q37320147-C5606EF7-7D02-4F8A-8691-9DEEE1FE8117 Q37388288-ED2B2CCB-DD31-4242-A76F-B275010C4569 Q37497786-C89B5839-CC33-461D-A026-D1A4E2BF3B8F Q37664059-D611F048-8FEA-48F2-9C43-9CE46FB87CE6 Q37772518-408305D8-182C-469D-BF3A-4C6C8F4F781B Q37853197-1ECCF340-29BB-4E7F-A3B3-98BF989FB7DD Q37942501-D0E3A592-34D7-445B-964B-EB967A60CD1A Q37989884-8C428EC1-145C-4863-8EF0-BD96B9B5C153 Q38011249-BD70F5AA-A647-4B22-9697-6E54BD4C2A0E Q38064483-E84FE137-EFC3-453F-BD2F-3CBD987A0ACB Q38096056-5A1943B5-A279-4641-814C-542F0170AF8E Q38161937-8666AFAA-BBCB-4A6D-9FD8-D5385510ACD1 Q38193822-89F2E05F-8E32-489E-BC73-C04A4F22C3CB Q38727211-4EE10929-7584-4CAF-ABBD-E9E346D86AC8 Q38741706-9F2CE35A-91BD-4D36-9E1B-1DD74B2B25DF Q38841677-83783909-E57D-410E-80CB-AD1F076866BF Q38895939-7E3DC757-5344-452A-BE1C-CE0D2B2529CA Q39377049-D9E7355A-2BC3-4A89-8481-EE51BFCAB2C0 Q39455092-6F4A98B9-B853-48EE-8253-35B95A396F7D

P2860

Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies.

http://www.wikidata.org/entity/Q34632118

description

2007 nî lūn-bûn

@nan

2007 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Oral resiquimod in chronic HCV ...... ouble-blind phase IIa studies.

@ast

Oral resiquimod in chronic HCV ...... ouble-blind phase IIa studies.

@en

Oral resiquimod in chronic HCV ...... ouble-blind phase IIa studies.

@nl

type

label

Oral resiquimod in chronic HCV ...... ouble-blind phase IIa studies.

@ast

Oral resiquimod in chronic HCV ...... ouble-blind phase IIa studies.

@en

Oral resiquimod in chronic HCV ...... ouble-blind phase IIa studies.

@nl

prefLabel

Oral resiquimod in chronic HCV ...... ouble-blind phase IIa studies.

@ast

Oral resiquimod in chronic HCV ...... ouble-blind phase IIa studies.

@en

Oral resiquimod in chronic HCV ...... ouble-blind phase IIa studies.

@nl

P1433

Q34632118-A53D8196-3205-4B07-B009-A537F23FE32D

P1476

Q34632118-17DECD82-D0A3-43AD-BE99-21ACEC3FD307

P2093

Q34632118-1293177F-0953-45C5-B5CA-E93EB7819404

Q34632118-253B3A02-9527-4685-9417-44A4FD9A114E

Q34632118-44C09434-B5C5-4076-A61E-CBC027A1FF7E

Q34632118-6181D9D3-4343-4EBD-B3B3-11BB7DFECB87

Q34632118-8B6C7EFE-CD7A-43C4-B2E2-ADAC4797E511

Q34632118-B82C8A44-852A-417E-86D7-A422C70C717B

Q34632118-DE10E480-8F22-4176-BE99-09D2B3D50DD4

P304

Q34632118-2697033D-DF46-46E1-BBB6-3FCBEA9B78DD

P31

Q34632118-89AAC1F4-6877-4E6F-B9E4-1E006F848D18

P356

Q34632118-BF14E7DC-D9F0-40CC-A962-588E3062FA4F

P433

Q34632118-DD7A1830-EF35-4E0F-A2BA-49251B4AC86A

P478

Q34632118-EC32FF08-D96F-45F9-9504-353200FEB5C5

P577

Q34632118-5FD69620-2B26-4596-B046-5929848CD653

P5875

Q34632118-A9461FAA-AB35-48F2-A5C8-2C255C61F0B2

P698

Q34632118-B6D6D0BF-B592-465D-BF73-651C0006B202

P921

Q34632118-5B15054F-84EF-4173-9D7E-14DF31D511E5

P356

J.JHEP.2007.02.025

P1433

Journal of Hepatology

P1476

Oral resiquimod in chronic HCV ...... ouble-blind phase IIa studies.

@en

P2093

Dominque Guyader

http://www.w3.org/2001/XMLSchema#string

Heather Patton

http://www.w3.org/2001/XMLSchema#string

John G McHutchison

http://www.w3.org/2001/XMLSchema#string

Myron J Tong

http://www.w3.org/2001/XMLSchema#string

Paul J Pockros

http://www.w3.org/2001/XMLSchema#string

Terry Wright

http://www.w3.org/2001/XMLSchema#string

Tze-Chiang Meng

http://www.w3.org/2001/XMLSchema#string

P304

174-182

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JHEP.2007.02.025

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P577

2007-05-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6302453

http://www.w3.org/2001/XMLSchema#string

P698

17532523

http://www.w3.org/2001/XMLSchema#string

P921